Tumor stroma and the antitumor immune response

Tumor Induced Immune Suppression: Mechanisms and Therapeutic Reversal

Volumn , Issue , 2008, Pages 281-294

  Zhang, Bin ^a   Rowley, Donald A ^a   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054919272     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69118-3_13     Document Type: Chapter

References (57)

1. Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J. H., et al. (2006). Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12: 878-887.
2. Antony, P. A., Piccirillo, C. A., Akpinarli, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C., Chan, C. C., Klebanoff, C. A., Overwijk, W. W., et al. (2005). CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:2591-2601.
3. Arlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M., Panicali, D., Beetham, P., Tsang, K. Y., Grosenbach, D. W., Feldman, J., et al. (2006). A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12:1260-1269.
4. Brent, L., and Medawar, P. (1966). Quantitative studies on tissue transplantation immunity. 8. The effects of irradiation. Proc Royal Soc Lond Ser B Biol Sci 165:413-423.
5. Bubenik, J. (2003). Tumour MHC class I downregulation and immunotherapy (review). Oncol Rep 10:2005-2008.
6. Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005). Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J ExpMed 202:1691-1701.
7. Ciernik, I. F., Romero, P., Berzofsky, J. A., and Carbone, D. P. (1999). Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope. Int J Radiat Oncol Biol Phys 45:735-741.
8. Demaria, S., Bhardwaj, N., McBride, W. H., and Formenti, S. C. (2005). Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 63:655-666.
9. Dudley, M. E., and Rosenberg, S. A. (2003). Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666-675.
10. Dvorak, H. F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1659.
11. Ferrara, N., Mass, R. D., Campa, C., and Kim, R. (2007). Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 58:491-504.
12. Gabrilovich, D. I. (2007). Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol 8:2-3.
13. Ganss, R., Ryschich, E., Klar, E., Arnold, B., and Hammerling, G. J. (2002). Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 62:1462-1770.
14. Garin-Chesa, P., Old, L. J., and Rettig, W. J. (1990). Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 87:7235-7239.
15. Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005a). Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumorspecific CD8+ T cells. J ExpMed 202:907-912.
16. Gattinoni, L., Klebanoff, C. A., Palmer, D. C., Wrzesinski, C., Kerstann, K., Yu, Z., Finkelstein, S. E., Theoret, M. R., Rosenberg, S. A., and Restifo, N. P. (2005b). Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115:1616-1626.
17. Gattinoni, L., Powell, D. J. Jr, Rosenberg, S. A., Restifo, N. P. (2006). Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6:383-393.
18. Gribben, J. G., Ryan, D. P., Boyajian, R., Urban, R. G., Hedley, M. L., Beach, K., Nealon, P., Matulonis, U., Campos, S., Gilligan, T. D., et al. (2005). Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 11:4430-4436.
19. Heath, W. R., and Carbone, F. R. (2005). Coupling and cross-presentation. Nature 434:27-28.
20. Hicklin, D. J., Marincola, F. M., and Ferrone, S. (1999). HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5:178-186.
21. Ho, W. Y., Blattman, J. N., Dossett, M. L., Yee, C., and Greenberg, P. D. (2003). Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3:431-437.
22. Holler, P. D., Chlewicki, L. K., and Kranz, D. M. (2003). TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol 4:55-62.
23. Holler, P. D., and Kranz, D. M. (2003). Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 18:255-264.
24. Ibe, S., Qin, Z., Schuler, T., Preiss, S., and Blankenstein, T. (2001). Tumor rejection by disturbing tumor stroma cell interactions. J ExpMed 194:1549-1559.
25. Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G.M., et al. (1993). Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-465.
26. Kelly, T. (2005). Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cellsurface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat 8:51-58.
27. Khong, H. T., Wang, Q. J., and Rosenberg, S. A. (2004). Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 27:184-190.
28. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844.
29. Klebanoff, C. A., Gattinoni, L., Torabi-Parizi, P., Kerstann, K., Cardones, A. R., Finkelstein, S. E., Palmer, D. C., Antony, P. A., Hwang, S. T., Rosenberg, S. A., et al. (2005). Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 102:9571-9576.
30. Klein, E., and Klein, G. (1972). Specificity of homograft rejection in vivo, assessed by inoculation of artificially mixed compatible and incompatible tumor cells. Cell Immunol 5:201-208.
31. Lake, R. A., and Robinson, B.W. (2005). Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 5:397-405.
32. Liu, K., Caldwell, S. A., and Abrams, S. I. (2005). Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gammaregulated gene expression. Cancer Res 65:4376-4388.
33. Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., and Lord, E. M. (2005). Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigenspecific effector cells that traffic to the tumor. J Immunol 174:7516-7523.
34. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S.M., Supko, J. G., Haluska, F. G., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139.
35. Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129.
36. Nair, S., Boczkowski, D., Moeller, B., Dewhirst, M., Vieweg, J., and Gilboa, E. (2003). Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102:964-971.
37. Neijssen, J., Herberts, C., Drijfhout, J. W., Reits, E., Janssen, L., and Neefjes, J. (2005). Crosspresentation by intercellular peptide transfer through gap junctions. Nature 434:83-88.
38. Niederman, T. M., Ghogawala, Z., Carter, B. S., Tompkins, H. S., Russell, M. M., and Mulligan, R. C. (2002). Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA 99:7009-7014.
39. Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., and Robinson, B. W. (2003). Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170:4905-4913.
40. Prehn, R. T. (1973). Destruction of tumor as an "innocent bystander" in an immune response specifically directed against nontumor antigens. Isr J Med Sci 9:375-379.
41. Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., Wansley, E. K., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006). Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J ExpMed 203:1259-1271.
42. Sanchez-Perez, L., Kottke, T., Diaz, R. M., Ahmed, A., Thompson, J., Chong, H., Melcher, A., Holmen, S., Daniels, G., and Vile, R. G. (2005). Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res 65:2009-2017.
43. Schreiber, H. (ed.) (2003). Tumor Immunology, 5th edn. Philadelphia, PA: Lippincott-Williams & Wilkins, pp. 1557-1592.
44. Scott, A.M., Wiseman, G., Welt, S., Adjei, A., Lee, F. T., Hopkins, W., Divgi, C. R., Hanson, L. H., Mitchell, P., Gansen, D. N., et al. (2003). A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9:1639-1647.
45. Seemayer, T. A., Lagace, R., Schurch, W., and Tremblay, G. (1979). Myofibroblasts in the stroma of invasive and metastatic carcinoma: a possible host response to neoplasia. Am J Surg Pathol 3:525-533.
46. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
47. Spiotto, M. T., Rowley, D. A., and Schreiber, H. (2004). Bystander elimination of antigen loss variants in established tumors. Nat Med 10:294-298.
48. Spiotto, M. T., and Schreiber, H. (2005). Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun 5:8.
49. Sweeney, C. J., Miller, K. D., and Sledge, G. W. Jr (2003). Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med 9:24-29.
50. Weissman, I. L. (1973). Tumor immunity in vivo: evidence that immune destruction of tumor leaves "bystander" cells intact. J Natl Cancer Inst 51:443-448.
51. Wesley, U. V., Albino, A. P., Tiwari, S., and Houghton, A. N. (1999). A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J ExpMed 190:311-322.
52. Wheeler, C. J., Das, A., Liu, G., Yu, J. S., and Black, K. L. (2004). Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10:5316-5326.
53. Yamshchikov, G. V., Mullins, D. W., Chang, C. C., Ogino, T., Thompson, L., Presley, J., Galavotti, H., Aquila, W., Deacon, D., Ross, W., et al. (2005). Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol 174:6863-6871.
54. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S.M., Chen, H. X., and Rosenberg, S. A. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434.
55. Yu, Z., Theoret, M. R., Touloukian, C. E., Surman, D. R., Garman, S. C., Feigenbaum, L., Baxter, T. K., Baker, B. M., and Restifo, N. P. (2004). Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest 114:551-559.
56. Zhang, B., Bowerman, N. A., Salama, J. K., Schmidt, H., Spiotto, M. T., Schietinger, A., Yu, P., Fu, Y. X., Weichselbaum, R. R., Rowley, D. A., et al. (2007). Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J ExpMed 204:49-55.
57. Zhou, G., Lu, Z., McCadden, J. D., Levitsky, H. I., and Marson, A. L. (2004). Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J ExpMed 200:1581-1592.